Insights into the genomic landscape of MYD88 wild-type Waldenström macroglobulinemia
Zachary R. Hunter(Harvard University), Steven P. Treon(Dana-Farber Cancer Institute), Cristina Jiménez(Central European Institute of Technology), Kenneth C. Anderson(Dana-Farber Cancer Institute), Mehmet Samur(Dana-Farber Cancer Institute), Amanda Kofides(Shaanxi Research Association for Women and Family), Gloria Chan(Shaanxi Research Association for Women and Family), Nikhil C. Munshi(Dana-Farber Cancer Institute), Maria Demos(Shaanxi Research Association for Women and Family), Nickolas Tsakmaklis(Dana-Farber Cancer Institute), Manit Munshi(Dana-Farber Cancer Institute), Joshua Gustine(Boston University), Kirsten Meid(Shaanxi Research Association for Women and Family), Toni Dubeau(Shaanxi Research Association for Women and Family), Guang Yang(Blueprint Medicines (United States)), Xia Liu(National Clinical Research), Lian Xu(Huazhong Agricultural University), Jorge J. Castillo(Dana-Farber Cancer Institute), Jiaji Chen(Harvard University), Christopher J. Patterson(Dana-Farber Cancer Institute)
Cited by 90
Related Papers
Signatures of mutational processes in human cancer
|Nature|2013|10.1k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k
International uniform response criteria for multiple myeloma
|Leukemia|2006|2.6k
Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group
|Journal of Clinical Oncology|2015|2.2k
Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma
|New England Journal of Medicine|2019|1.7k